drugset / Trial / NCT00469859
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lestaurtinib together with cytarabine and idarubicin may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lestaurtinib when given together with cytarabine and idarubicin and to see how well they work in treating younger patients with relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2007-06
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lestaurtinib | Small molecule | 50 mg/m2 | Oral |
| Subject | lestaurtinib | Small molecule | 62.5 mg/m2 | Oral |
| Background | Cytarabine | Small molecule | — | Intravenous |
| Background | Idarubicin | Small molecule | — | Intravenous |